C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis

Background: Patients critically ill with coronavirus disease-2019 (COVID-19) feature hyperinflammation, and the associated biomarkers may be beneficial for risk stratification. We aimed to investigate the association between several biomarkers, including serum C-reactive protein (CRP), procalcitonin (PCT), D-dimer, and serum ferritin, and COVID-19 severity. Methods: We performed a comprehensive systematic literature search through electronic databases. The outcome of interest for this study was the composite poor outcome, which comprises mortality, acute respiratory distress syndrome, need for care in an intensive care unit, and severe COVID-19. Results: A total of 5350 patients were pooled from 25 studies. Elevated CRP was associated with an increased composite poor outcome [risk ratio (RR) 1.84 (1.45, 2.33), p < 0.001; I2: 96%] and its severe COVID-19 (RR 1.41; I2: 93%) subgroup. A CRP ⩾10 mg/L has a 51% sensitivity, 88% specificity, likelihood ratio (LR) + of 4.1, LR- of 0.5, and an area under curve (AUC) of 0.84. An elevated PCT was associated with an increased composite poor outcome [RR 3.92 (2.42, 6.35), p < 0.001; I2: 85%] and its mortality (RR 6.26; I2: 96%) and severe COVID-19 (RR 3.93; I2: 63%) subgroups. A PCT ⩾0.5 ng/ml has an 88% sensitivity, 68% specificity, LR+ of 2.7, LR- of 0.2, and an AUC of 0.88. An elevated D-dimer was associated with an increased composite poor outcome [RR 2.93 (2.14, 4.01), p < 0.001; I2: 77%], including its mortality (RR 4.15; I2: 83%) and severe COVID-19 (RR 2.42; I2: 58%) subgroups. A D-dimer >0.5 mg/L has a 58% sensitivity, 69% specificity, LR+ of 1.8, LR- of 0.6, and an AUC of 0.69. Patients with a composite poor outcome had a higher serum ferritin with a standardized mean difference of 0.90 (0.64, 1.15), p < 0.0001; I2: 76%. Conclusion: This meta-analysis showed that an elevated serum CRP, PCT, D-dimer, and ferritin were associated with a poor outcome in COVID-19. The reviews of this paper are available via the supplemental material section.

[1]  Lei Liu,et al.  Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia (COVID-19) , 2020 .

[2]  Hongzhou Lu,et al.  Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China , 2020, medRxiv.

[3]  G. Zhen,et al.  Radiographic Findings and other Predictors in Adults with Covid-19 , 2020, medRxiv.

[4]  R. Pranata,et al.  Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[5]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[6]  Chang Hu,et al.  Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China , 2020, medRxiv.

[7]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[8]  Hongzhou Lu,et al.  Clinical Characteristics of SARS-CoV-2 Infections Involving 325 Hospitalized Patients outside Wuhan , 2020 .

[9]  Prognostic value of the biomarkers procalcitonin, interleukin-6 and C-reactive protein in severe sepsis , 2012 .

[10]  A. Creamer,et al.  Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy , 2019, Breathe.

[11]  Fang Liu,et al.  Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 , 2020, Journal of Clinical Virology.

[12]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[13]  S. Mimura,et al.  Non-Severe vs Severe Symptomatic COVID-19: 104 Cases from the Outbreak on the Cruise Ship 'Diamond Princess' in Japan , 2020 .

[14]  D. Musher,et al.  Procalcitonin to distinguish viral from bacterial pneumonia: A systematic review and meta-analysis. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Yuhui Yang,et al.  The Potential Role of IL-6 in Monitoring Coronavirus Disease 2019 , 2020 .

[16]  Ke Ma,et al.  Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study , 2020, BMJ.

[17]  W. Tu,et al.  Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Huan Li,et al.  Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis , 2020, The Journal of Infection.

[19]  C. Akdis,et al.  Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.

[20]  A. Falanga,et al.  ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[21]  G. Lau,et al.  Clinical Characteristics Predicting Progression of COVID-19 , 2020 .

[22]  Zhi-heng Liu,et al.  COVID-19 Myocarditis and Severity Factors： An Adult Cohort Study , 2020, medRxiv.

[23]  J. Ashworth,et al.  Role of C-Reactive Protein at Sites of Inflammation and Infection , 2018, Front. Immunol..

[24]  Mandeep R. Mehra,et al.  COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal , 2020, The Journal of Heart and Lung Transplantation.

[25]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[27]  Shikai Yu,et al.  Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study , 2020, medRxiv.

[28]  T. van der Poll,et al.  Coagulation and sepsis. , 2017, Thrombosis research.

[29]  The usefulness of C-reactive protein and procalcitonin to predict prognosis in septic shock patients: A multicenter prospective registry-based observational study , 2019, Scientific Reports.

[30]  W. Cao,et al.  Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia , 2020, Emerging microbes & infections.

[31]  Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions , 2019, BMC Infectious Diseases.

[32]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[33]  Chang Hu,et al.  Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China , 2020, Journal of Clinical Virology.

[34]  E. Giamarellos‐Bourboulis,et al.  Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis , 2019, Front. Immunol..

[35]  M. Barbagallo,et al.  Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature , 2020, Frontiers in Medicine.

[36]  S. Mimura,et al.  The clinical characteristics of COVID-19: a retrospective analysis of 104 patients from the outbreak on board the Diamond Princess cruise ship in Japan , 2020, medRxiv.

[37]  M. Nijsten,et al.  Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. , 2018, The Lancet. Infectious diseases.

[38]  Yan Zhao,et al.  The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China , 2020, Clinical Immunology.

[39]  Huan Li,et al.  Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  Y. Xiong,et al.  Clinical features and treatment of COVID‐19 patients in northeast Chongqing , 2020, Journal of medical virology.

[41]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[42]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[43]  R. Pranata,et al.  Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression , 2020, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[44]  Mario Plebani,et al.  Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis , 2020, Clinica Chimica Acta.

[45]  COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China , 2020, Allergy.

[46]  Maria Lengquist,et al.  C-reactive protein as a prognostic factor in intensive care admissions for sepsis: A Swedish multicenter study. , 2019, Journal of critical care.

[47]  R. Pranata,et al.  Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis , 2020, Postgraduate Medical Journal.

[48]  R. Pranata,et al.  Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19–systematic review, meta-analysis, and meta-regression , 2020, Journal of Stroke and Cerebrovascular Diseases.

[49]  T. Guo,et al.  Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China , 2020, medRxiv.

[50]  Baoju Wang,et al.  Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients , 2020, EBioMedicine.

[51]  World Health Organization,et al.  Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance , 2020, Pediatria i Medycyna Rodzinna.

[52]  Huan Li,et al.  Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan, China , 2020, medRxiv.

[53]  P. Schuetz,et al.  Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future , 2011, BMC medicine.

[54]  A. López-Guillermo,et al.  Adult haemophagocytic syndrome , 2014, The Lancet.

[55]  R. Pranata,et al.  Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19. , 2020, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[56]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[57]  R. Pranata,et al.  Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis , 2020, Journal of Intensive Care.